5.4(top 5%)
impact factor
4.6K(top 5%)
papers
164.9K(top 2%)
citations
155(top 2%)
h-index
6.7(top 5%)
extended IF
6.0K
all documents
176.8K
doc citations
215(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism2013679
2Pancreatic β‐cell mass in European subjects with type 2 diabetesDiabetes, Obesity and Metabolism2008672
3Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes, Obesity and Metabolism2007605
4Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1cDiabetes, Obesity and Metabolism2010597
5Adiponectin – a key adipokine in the metabolic syndromeDiabetes, Obesity and Metabolism2006548
6Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism2013545
7Incretin hormones: Their role in health and diseaseDiabetes, Obesity and Metabolism2018514
8Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism2012491
9Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal womenDiabetes, Obesity and Metabolism2006486
10Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism2007481
11Insulin‐associated weight gain in diabetes – causes, effects and coping strategiesDiabetes, Obesity and Metabolism2007457
12Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism2013436
13Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes, Obesity and Metabolism2011434
14Role of vitamin D in the pathogenesis of type 2 diabetes mellitusDiabetes, Obesity and Metabolism2008419
15The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism2012409
16COVID‐19 infection may cause ketosis and ketoacidosisDiabetes, Obesity and Metabolism2020409
17Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes, Obesity and Metabolism2015403
18Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes, Obesity and Metabolism2006399
19Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes, Obesity and Metabolism2014398
20Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysisDiabetes, Obesity and Metabolism2016370
21Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisDiabetes, Obesity and Metabolism2018355
22Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesityDiabetes, Obesity and Metabolism2007353
23Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetesDiabetes, Obesity and Metabolism2012352
24Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes, Obesity and Metabolism2011350
25An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelinesDiabetes, Obesity and Metabolism2020338
26Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitorsDiabetes, Obesity and Metabolism2016336
27Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysisDiabetes, Obesity and Metabolism2020335
28Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trialDiabetes, Obesity and Metabolism2014326
29Advanced glycation endproducts: what is their relevance to diabetic complications?Diabetes, Obesity and Metabolism2007320
30Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesityDiabetes, Obesity and Metabolism2017320
31Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysisDiabetes, Obesity and Metabolism2017318
32Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trialsDiabetes, Obesity and Metabolism2011313
33Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trialsDiabetes, Obesity and Metabolism2013312
34Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literatureDiabetes, Obesity and Metabolism2010299
35Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controlsDiabetes, Obesity and Metabolism2014298
36The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitusDiabetes, Obesity and Metabolism2012290
37Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetesDiabetes, Obesity and Metabolism2012289
38Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes, Obesity and Metabolism2010284
39Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes, Obesity and Metabolism2011276
40GLP‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependenceDiabetes, Obesity and Metabolism2013276
41Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trialDiabetes, Obesity and Metabolism2009273
42New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)Diabetes, Obesity and Metabolism2015272
43Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes, Obesity and Metabolism2011267
44Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism2011267
45Diabetes is an inflammatory disease: evidence from traditional Chinese medicinesDiabetes, Obesity and Metabolism2011266
46Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic reviewDiabetes, Obesity and Metabolism2018266
47Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes, Obesity and Metabolism2007263
48Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trialsDiabetes, Obesity and Metabolism2018262
49Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes, Obesity and Metabolism2009261
50Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism2019261